Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31102359 | 0.86 | CHEK1 (0.49) | IMPDH2IMPDH1GPR84CHEK1CCNT1 | |
| SCHEMBL27708724 | 0.85 | IMPDH2 (0.56) | IMPDH2IMPDH1GPR84CHEK1CCNT1 | |
| SCHEMBL27727436 | 0.81 | GPR84 (0.53) | GPR84DYRK1AALDH1A1NR4A2SLC6A4 | |
| SCHEMBL28903106 | 0.79 | EGFR (0.46) | IMPDH2IMPDH1GPR84DYRK1AALDH1A1 | |
| SCHEMBL30665808 | 0.78 | IMPDH2 (0.56) | IMPDH2IMPDH1GPR84CHEK1CCNT1 | |
| SCHEMBL394651 | 0.78 | IMPDH2 (0.56) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL187169 | 0.78 | IMPDH2 (0.56) | IMPDH2IMPDH1GPR84CCNT1CDK9 | |
| SCHEMBL13181942 | 0.78 | IMPDH2 (0.56) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL28774173 | 0.78 | IMPDH2 (0.56) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL6600237 | 0.78 | IMPDH2 (0.56) | IMPDH2IMPDH1CCNT1CDK9HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| CN-101219986-B | 3-cyanogen radical indole compounds and its synthetic method | SHANGHAI CHEMPARTNER CO LTD | 2011-08-10 | — | — | CN | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| CN-101219986-A | 3-cyanogen radical indole compounds and its synthetic method | SHANGHAI CHEMPARTNER CO LTD (CN) | 2008-07-16 | — | — | CN | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | IMPDH2 250/4885IMPDH1 241/4885GPR84 3055/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | IMPDH2 477/4885IMPDH1 519/4885GPR84 2689/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | IMPDH2 1869/4885IMPDH1 1621/4885GPR84 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.